Akero Therapeutics updates: news & description

Presence

Akero Therapeutics is a biotechnology company that develops treatments for serious liver and metabolic diseases. Its main services are drug research and clinical development for patients, healthcare providers, and medical partners.

Akero Therapeutics products and services overview:

Liver disease therapies
Metabolic disease therapies
Drug research
Clinical development

Revenue: ~$0 million

Employees: 120

Headquarters: South San Francisco, United States (USA)

Akero Therapeutics is owned by Novo Nordisk.

Novo Nordisk is one of the...

Novo Nordisk is a company listed under the stock ticker NOVO (DK).

Novo Nordisk has a direct presence in 13 countries.

Novo Nordisk has 19 subsidiaries including Akero Therapeutics, Cardior Pharmaceuticals and Inversago Pharma.

They are in:

Acquisition, funding and merger involving Novo Nordisk.

Novo Nordisk has announced the acquisition of Akero Therapeutics (posted on October 9 2025).

Executives

View the org chart displaying its 28 main executives

Most searched biographies at Akero Therapeutics

Popular executive movements at Akero Therapeutics

Brittany De Temple, Vice President, Development Operations, has left the company (posted on February 6 2026).
Jonathan Young, who was Executive Vice President and Chief Operating Officer, is promoted to Chief Executive Officer (posted on February 5 2026).
Kitty Yale, Executive Vice President, Chief Development Officer and Director, has left the company (posted on February 5 2026).

Click here to view some more movements at Akero Therapeutics

Popular executive movements at Novo Nordisk

Dennis Persson, Head of Security Partnering, Infrastructure & Technology, has left the company (posted on May 26 2026).
Christine Farmer, Vice President, M&A Integrations, has left the company (posted on May 26 2026).
Tanja Villumsen, Director, Employee Representative, will leave the company on Mar. 26, 2026 (posted on March 3 2026).

Click here to view some more movements at Novo Nordisk

Create your alert
to follow the executive moves at Akero Therapeutics.